CL2009002040A1 - Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis. - Google Patents

Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis.

Info

Publication number
CL2009002040A1
CL2009002040A1 CL2009002040A CL2009002040A CL2009002040A1 CL 2009002040 A1 CL2009002040 A1 CL 2009002040A1 CL 2009002040 A CL2009002040 A CL 2009002040A CL 2009002040 A CL2009002040 A CL 2009002040A CL 2009002040 A1 CL2009002040 A1 CL 2009002040A1
Authority
CL
Chile
Prior art keywords
thrombosis
quinazolin
thiophen
dioxo
methylamino
Prior art date
Application number
CL2009002040A
Other languages
English (en)
Inventor
Emma Sharp
Louisa Jane Quegan
Anjali Pandey
Juan Wang
Matthew Nieder
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009002040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of CL2009002040A1 publication Critical patent/CL2009002040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea; formas cristalinas de dichas sales; método de preparación; composición farmacéutica, útil para prevenir o tratar trombosis y condiciones patológicas relacionadas con trombosis.
CL2009002040A 2008-11-05 2009-11-05 Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis. CL2009002040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/265,699 US20090156620A1 (en) 2007-05-02 2008-11-05 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Publications (1)

Publication Number Publication Date
CL2009002040A1 true CL2009002040A1 (es) 2010-09-10

Family

ID=41460405

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009002040A CL2009002040A1 (es) 2008-11-05 2009-11-05 Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis.

Country Status (14)

Country Link
US (2) US20090156620A1 (es)
EP (1) EP2358706A1 (es)
JP (1) JP2012508243A (es)
KR (1) KR20110093843A (es)
CN (1) CN102272130A (es)
AR (1) AR075097A1 (es)
AU (1) AU2009313565A1 (es)
BR (1) BRPI0921649A2 (es)
CA (1) CA2742601A1 (es)
CL (1) CL2009002040A1 (es)
MX (1) MX2011004841A (es)
RU (1) RU2011122385A (es)
TW (1) TW201022252A (es)
WO (1) WO2010054020A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1951254E (pt) * 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
CN103288761B (zh) * 2012-02-25 2017-08-11 浙江华海药业股份有限公司 一种合成1，2，3，4‑喹唑啉‑2，4‑二酮衍生物的新方法
AU2017364349A1 (en) * 2016-11-28 2019-07-11 Sarin PARAYIL Novel organic crystalline salt of haloacetic acid
CN115490643A (zh) * 2022-11-21 2022-12-20 南京合创药业有限公司 一种一锅法合成3-二氯苯基-6-氟-2,4(1h,3h)-喹唑啉二酮的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
PT1951254E (pt) * 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
CA2686203A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Also Published As

Publication number Publication date
CN102272130A (zh) 2011-12-07
BRPI0921649A2 (pt) 2016-02-10
AR075097A1 (es) 2011-03-09
WO2010054020A1 (en) 2010-05-14
US20090156620A1 (en) 2009-06-18
EP2358706A1 (en) 2011-08-24
KR20110093843A (ko) 2011-08-18
JP2012508243A (ja) 2012-04-05
RU2011122385A (ru) 2012-12-20
MX2011004841A (es) 2011-07-28
AU2009313565A1 (en) 2010-05-14
US20120129876A1 (en) 2012-05-24
CA2742601A1 (en) 2010-05-14
TW201022252A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CL2009002040A1 (es) Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis.
CY1124208T1 (el) Αλατα η συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
BRPI0821688A2 (pt) mistura para o tratamento de fertilizantes contendo uréia
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0918586A2 (pt) compostos, composições e métodos de uso dos mesmos para a modulação dos níveis de ácido úrico
GT201200181A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0916593A2 (pt) processo para modificação contínua de gesso diidratado e gesso diidratado modificado obtido através do processo.
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0906786A2 (pt) Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0810076A2 (pt) Processo para preparar compostos, uso de compostos, composto, e mistura.
CL2008003088A1 (es) Metodo de preparacion de la sal de de maleato de (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi)anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilanino)-2-butenamida; formas cristalinas anhidra y monohidrato de la sal maleato; metodo de preparacion; composicion farmaceutica; utiles en el tratamiento de cancer.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
BRPI0919876A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0913173A2 (pt) "aditivo para inibição de corrosão causada por ácido e método de produção e uso do mesmo"